Publications in collaboration with researchers from The Bristol-Myers Squibb Children's Hospital (14)

2024

  1. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

2022

  1. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

    The Lancet Oncology, Vol. 23, Núm. 1, pp. 77-90

2021

  1. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis

    Journal of Hepatology, Vol. 75, Núm. 3, pp. 600-609

  2. OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors

    Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

2019

  1. An integrative approach to inform optimal administration of OX40 agonist antibodies in patients with advanced solid tumors

    Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6709-6720

2018

  1. CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes

    Cancer Immunology Research, Vol. 6, Núm. 1, pp. 69-78

  2. Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB)

    OncoImmunology, Vol. 7, Núm. 1

2017

  1. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502

  2. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

    Clinical Cancer Research, Vol. 23, Núm. 8, pp. 1929-1936

2016

  1. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming

    Cancer Research, Vol. 76, Núm. 20, pp. 5994-6005

  2. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

    Drugs, Vol. 76, Núm. 9, pp. 925-945

2015

  1. Evolving synergistic combinations of targeted immunotherapies to combat cancer

    Nature Reviews Cancer, Vol. 15, Núm. 8, pp. 457-472

2013

  1. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes

    Journal of Immunology, Vol. 190, Núm. 12, pp. 6694-6706